Results 91 to 100 of about 74,509 (297)
Tailoring therapy for heart failure: the pharmacogenomics of adrenergic receptor signaling. [PDF]
, 2014 Heart failure is one of the leading causes of mortality in Western countries, and β-blockers are a cornerstone of its treatment. However, the response to these drugs is variable among individuals, which might be explained, at least in part, by genetic ...
Barrese, V +3 more
core +2 more sources
Clinical Pharmacology &Therapeutics, EarlyView.Pharmacogenomics implementation efforts have increased over the last decade, but no published prospective pharmacogenomics trials have formally evaluated utility in underrepresented populations. We present final results from the ACCOuNT trial, a multi‐institutional prospective study [NCT03225820] in which African American inpatients were genotyped and ...
Zhong Huang +17 more
wiley +1 more source
Economic burden of adverse drug reactions and potential for pharmacogenomic testing in Singaporean adults. [PDF]
, 2019 Adverse drug reactions (ADRs) contribute to hospitalization but data on its economic burden is scant. Pre-emptive pharmacogenetic (PGx) testing can potentially reduce ADRs and its associated costs.
Brunham, Liam R +6 more
core +1 more source
Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency [PDF]
, 2010 Objective: Patients with congenital adrenal hyperplasia due to P450 oxidoreductase (POR) deficiency(ORD) present with disordered sex development and glucocorticoid deficiency.
Arlt +25 more
core +2 more sources
Unraveling Novel Genetic Determinants of Thiopurine Response Via TWAS
Clinical Pharmacology &Therapeutics, EarlyView.Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Thiopurines such as 6‐mercaptopurine (6MP) are essential in ALL maintenance therapy. However, dose‐limiting toxicities can significantly disrupt treatment. While genetic variants in TPMT and NUDT15 are known to affect thiopurine response, many patients with normal function ...
Carlotta Bidoli +5 more
wiley +1 more source
Pharmacogenomics of Paclitaxel [PDF]
Pharmacogenomics, 2010 The microtubule-stabilizing drug paclitaxel is a cytotoxic agent widely used for the treatment of a variety of tumor types. Since its introduction to the clinic, modifications to the administration schedule and treatments for hypersensitivity reactions and neutropenia have significantly improved paclitaxel therapy.
openaire +2 more sources
Context, ethics and pharmacogenetics [PDF]
, 2006 Most of the literature on pharmacogenetics assumes that the main problems in implementing the technology will be institutional ones (due to funding or regulation) and that although it involves genetic testing, the ethical issues involved in ...
Adam M. Hedgecoe +58 more
core +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Pharmacogenomics enables the personalization of drug therapy by linking genetic variations to differences in drug metabolism, efficacy, and risk of adverse reactions. Genetic polymorphisms within cytochrome P450 (CYP) genes significantly affect enzyme activity, influencing drug plasma levels, responses, and safety.
Alex J. Coulter +4 more
wiley +1 more source
Head &Neck, EarlyView.ABSTRACT Background This study investigated the roles of single nucleotide variants (SNVs) in genes of CDDP metabolism and their association with kidney dysfunction in patients with head and neck squamous cell carcinoma (HNSCC). Methods A total of 109 patients with locally advanced HNSCC, treated with CDDP, had renal function evaluated by serum ...
Ericka Francislaine Dias Costa +4 more
wiley +1 more source
International Journal of Cancer, EarlyView.What's New? Colorectal cancer (CRC) frequently metastasizes to the liver, either synchronously with primary diagnosis or metachronously, after variable time intervals. Although implicated, the role of genetic factors in driving synchronous and metachronous disease progression remains uncertain.
Marie Rajtmajerova +16 more
wiley +1 more source